SEC Form 4 · accession 0001354488-17-000035
TG THERAPEUTICS, INC. · TGTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean A Power
Officer — CFO, Secretary and Treasurer
Period of report
Dec 30, 2016
Accepted (ET)
Jan 4, 2017 · 5:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001316
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 30, 2016 | A | 100,000 | $0.00 | A | 516,256 | D | |
| Common StockF4,F2 | Jan 4, 2017 | S | 8,816 | $4.55 | D | 507,440 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects a grant of restricted shares that will vest according to the following schedule: 17.5% on January 1, 2018; 17.5% on January 1, 2019; 35% on the later to occur of: (a) the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on December 31, 2016 and (b) June 30, 2019; and 30% on performance based thresholds associated with the Company?s clinical programs.
- F2Includes shares of restricted Common Stock, which vest over various time periods.
- F3In connection with the vesting of 15,000 shares on January 1, 2017, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Power's tax withholding obligations. Mr. Power had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.
- F4Represents the weighted average sales price.